IP Library Granted Patent US 10,047,077
Granted Patent B2
US 10,047,077 · App. 15/486,555 · Granted Aug 14, 2018

Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams

Inventor: Eric M. Gordon (Palo Alto, CA)
Assignee: SKYLINE ANTIINFECTIVES, INC.
C07D417/12C07B59/002C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,077
App. No.
15/486,555
Granted
Aug 14, 2018
Kind
B2
Abstract

Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.

Claims (25)

1. A compound of structural Formula (III):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein:

each of X and Y is independently selected from —CH 3 and —CD 3 ;

at least one of X and Y is —CD 3 ; and

the level of deuterium enrichment at each position denoted D is at least 50%.

2. The compound of claim 1 , having the structure:

3. The compound of claim 1 , having the structure:

4. The compound of claim 1 , having the structure:

5. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

6. The compound of claim 1 , wherein the level of deuterium enrichment at each position denoted D is at least 70%.

7. A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

8. The compound of claim 1 , wherein the level of deuterium enrichment at each position denoted D is at least 80%.

9. A pharmaceutical composition comprising the compound of claim 8 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

10. The compound of claim 1 , wherein the level of deuterium enrichment at each position denoted D is at least 90%.

11. A pharmaceutical composition comprising the compound of claim 10 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

12. The compound of claim 1 , wherein the level of deuterium enrichment at each position denoted D is at least 98%.

13. A pharmaceutical composition comprising the compound of claim 12 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

14. A compound having the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the level of deuterium enrichment at each position denoted D is at least 90%.

15. A pharmaceutical composition comprising the compound of claim 14 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

16. A compound having the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the level of deuterium enrichment at each position denoted D is at least 98%.

17. A pharmaceutical composition comprising the compound of claim 16 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

19. A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient.

Assignments (4)
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Mar 15, 2023
From: ARIXA PHARMACEUTICALS, INC.
To: ARIXA PHARMACEUTICALS, INC.
Reel/Frame 063825/0333 →
CHANGE OF NAME Recorded Mar 20, 2018
From: ARIXA PHARMACEUTICS, INC.
To: ARIXA PHARMACEUTICALS, INC.
Reel/Frame 045653/0074 →
CHANGE OF NAME Recorded Mar 16, 2018
From: SKYLINE ANTIINFECTIVES, INC.
To: ARIXA PHARMACEUTICS, INC.
Reel/Frame 045619/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: GORDON, ERIC M.
To: SKYLINE ANTINFECTIVES, INC.
Reel/Frame 042391/0731 →
Continuity (2)
Provisional Application 62322088 · Apr 13, 2016
Related Publication 20170298057A1 · Oct 19, 2017